Examkin

Psychiatry

814 questions

All types814Multiple choice418Multiple select68Matching191Ordering137
Question 801Question →

A 31-year-old man is evaluated in the clinic due to a one-month history of overwhelming sadness, severe fatigue, and a loss of interest in his usual hobbies. During this time, he has been sleeping up to 12 hours a day and has missed multiple days of work. His wife, who accompanies him, reports that four years ago he experienced a distinct two-week period where his behavior changed dramatically. During that time, he slept only two hours a night without feeling tired, obsessively pursued a chaotic new business venture, and spoke so rapidly that others could not interrupt him. He was not hospitalized during that episode and eventually returned to his baseline. He is currently taking no medications, and his medical history is unremarkable. Which of the following is the most appropriate pharmacologic intervention for this patient's current symptoms?

Show answer & explanation

Answer: Lurasidone

Answer

Lurasidone
The patient is currently experiencing a major depressive episode, but his history of a distinct period of decreased sleep, pressured speech, and excessive goal-directed behavior confirms a prior manic episode. Therefore, his diagnosis is bipolar I disorder, currently in a depressed episode. Lurasidone is an atypical antipsychotic that is FDA-approved and widely recommended as a first-line treatment for acute bipolar depression. It provides necessary antidepressant effects without the risk of triggering a manic switch.

Step-by-Step Solution

1
Identify the patient's current clinical syndrome.
The patient has a one-month history of depressed mood, anhedonia, fatigue, and hypersomnia, fulfilling the criteria for a major depressive episode.
Establishing the current affective state is necessary to understand the immediate treatment target.
2
Evaluate the patient's psychiatric history for previous mood episodes.
The patient has a history of a two-week period characterized by decreased need for sleep, pressured speech, and goal-directed activity, which meets the criteria for a past manic episode.
A history of mania changes the diagnosis from major depressive disorder (unipolar depression) to bipolar I disorder, profoundly altering the treatment algorithm.
3
Select the appropriate pharmacotherapy for acute bipolar depression.
Lurasidone is chosen because it is an effective, first-line agent for bipolar depression.
Antidepressant monotherapy must be avoided in bipolar disorder to prevent the induction of a manic switch.

Key Concept

Patients presenting with depressive symptoms must be carefully screened for a history of mania; bipolar depression should be treated with mood stabilizers or specific atypical antipsychotics (e.g., lurasidone, quetiapine), strictly avoiding antidepressant monotherapy.
Question 802Question →

A 24-year-old medical student is diagnosed with major depressive disorder and prescribed a daily dose of escitalopram. The physician counsels the patient extensively on what to expect over the coming months regarding efficacy and adverse effects. Arrange the following clinical developments in the typical chronological order of their occurrence following the initiation of continuous selective serotonin reuptake inhibitor (SSRI) therapy.

Drag items to arrange them in the correct order

Show answer & explanation

Answer

The sequence progresses from immediate adverse side effects (hours to days), to neurovegetative improvement (1-2 weeks), to subjective mood improvement (4-6 weeks), and finally maximal therapeutic response (8-12 weeks).
Understanding the timeline of SSRI response is critical for patient counseling and safety monitoring. Upon initiation, the sudden increase in serotonin acutely stimulates receptors, causing immediate adverse effects like nausea and jitteriness within hours to days. Over the first 1 to 2 weeks, neurovegetative symptoms (sleep, energy, appetite) begin to improve. Because energy returns before mood improves, patients are at a transiently increased risk for suicide. At 4 to 6 weeks, the necessary neuroplastic changes and receptor downregulation have occurred, leading to a noticeable lift in subjective depressed mood and anhedonia. Maximal therapeutic benefit is generally achieved at 8 to 12 weeks.

Step-by-Step Solution

1
Identify the immediate effects following the first dose of an SSRI.
Early serotonergic adverse effects appear first.
Blockade of the serotonin transporter (SERT) happens immediately, leading to acute 5-HT receptor stimulation in the gut and brain, causing nausea and jitteriness before any therapeutic neuroadaptation occurs.
2
Determine the initial signs of therapeutic efficacy.
Improvement in neurovegetative symptoms occurs next.
Physical symptoms like poor energy, insomnia, and altered appetite typically respond within the first 1 to 2 weeks of continuous treatment.
3
Determine the timeframe for core emotional symptom relief.
Subjective mood and anhedonia improve later in the course of treatment.
It takes approximately 4 to 6 weeks for sustained serotonin elevation to induce the necessary downregulation of presynaptic autoreceptors and promote hippocampal neurogenesis, which is required to lift the depressed mood.
4
Identify the endpoint for evaluating a medication trial.
Maximal therapeutic response is achieved last.
Complete clinical remission or the maximum possible benefit from a specific dose usually solidifies by 8 to 12 weeks.

Key Concept

Chronological timeline of SSRI therapeutic response and adverse effects
Question 803Question →

Paramedics bring a 31-year-old man to the emergency department after finding him unresponsive in a local park. On arrival, he is deeply obtunded with a respiratory rate of 4 breaths/minute and marked miosis. After successfully resuscitating the patient, the care team manages his subsequent hospital course and eventually discharges him to community-based care. Arrange the following clinical steps in the most appropriate chronological sequence for managing this patient's condition, from his initial emergency presentation through his long-term recovery.

Drag items to arrange them in the correct order

Show answer & explanation

Answer

The correct sequence is: 1) Initiate bag-valve-mask ventilation, 2) Administer intravenous naloxone, 3) Assess symptoms using the Clinical Opiate Withdrawal Scale (COWS), 4) Administer sublingual buprenorphine, 5) Refer to long-term psychosocial counseling.
The correct sequence mirrors the clinical progression of a patient surviving an opioid overdose and entering recovery. Airway and breathing must always be secured first (bag-valve-mask ventilation). Once oxygenation is established, naloxone is given to reverse the opioid toxicity. Following recovery from the acute overdose, the patient must be observed until they enter objective opioid withdrawal, measured by the COWS score. Only then is it safe to induce buprenorphine, a partial mu-agonist, because administering it too early causes severe precipitated withdrawal. Finally, outpatient psychosocial counseling is arranged for long-term maintenance.

Step-by-Step Solution

1
Address the immediate life-threatening emergency by supporting the patient's airway and breathing.
Hypoxia is reversed via bag-valve-mask ventilation.
Basic Life Support (BLS) protocols dictate that airway and breathing supersede all other interventions, including antidote administration.
2
Administer an opioid antagonist.
Naloxone displaces the opioid from mu-receptors, restoring the patient's intrinsic respiratory drive.
Naloxone is the definitive treatment for opioid-induced respiratory depression, but must follow airway stabilization.
3
Monitor the patient as the naloxone wears off and the original opioid is metabolized.
The patient transitions into opioid withdrawal, which is quantified using the COWS assessment.
Objective confirmation of withdrawal is required before starting maintenance therapy to avoid worsening the patient's condition.
4
Initiate medication-assisted treatment with a partial agonist.
Buprenorphine is given sublingually to relieve withdrawal symptoms and reduce cravings.
Because buprenorphine has a very high affinity for the mu-receptor but low intrinsic activity, giving it too early (while full agonists are present) causes precipitated withdrawal.
5
Establish outpatient psychiatric and social support.
The patient is linked to long-term psychosocial counseling.
Pharmacotherapy combined with behavioral interventions yields the highest long-term success rates in Substance-Related and Addictive Disorders.

Key Concept

Chronological management of opioid use disorder from acute overdose resuscitation to maintenance therapy
Question 804Question →

A 22-year-old man is evaluated in a dual-diagnosis residential facility. Two months ago, he was hospitalized following an episode of severe agitation where he claimed that government drones were injecting thoughts into his mind. This psychotic episode began immediately after a three-day binge of smoking methamphetamine. He was subsequently transferred to the current facility, where he has been monitored continuously and has had negative urine toxicology screens twice weekly for the past 7 weeks. Despite confirmed abstinence from all illicit substances during this 7-week period, the patient continues to experience daily auditory hallucinations and expresses the belief that the facility staff are government agents. He has not exhibited any significant depressive or manic symptoms. Which of the following is the most likely diagnosis?

Show answer & explanation

Answer: Schizophreniform disorder

Answer

Schizophreniform disorder
This patient presents with active-phase psychotic symptoms (delusions, auditory hallucinations) that have been present for exactly 2 months. To differentiate primary psychotic disorders, timeline is the crucial metric: symptoms lasting <1 month signify brief psychotic disorder, 1 to 6 months signify schizophreniform disorder, and >6 months signify schizophrenia. Furthermore, while his initial presentation was heavily associated with methamphetamine use, his symptoms have persisted for 7 weeks of strictly monitored abstinence. According to DSM-5 criteria, psychotic symptoms that persist for longer than 1 month after the cessation of acute substance intoxication or withdrawal indicate an underlying primary psychotic disorder, rather than a substance-induced state. Given the 2-month total duration and lack of mood symptoms, the most accurate diagnosis is schizophreniform disorder.

Step-by-Step Solution

1
Identify the primary psychiatric symptoms.
The patient exhibits active-phase psychotic symptoms including auditory hallucinations and persecutory delusions.
Establishing the presence of psychosis is the first step in formulating a differential diagnosis.
2
Determine the relationship between the symptoms and substance use.
The psychosis began after methamphetamine use but has persisted for 7 weeks despite confirmed abstinence.
If psychosis persists for >1 month after substance cessation, a primary psychotic disorder must be diagnosed instead of a substance-induced disorder.
3
Calculate the total continuous duration of the psychotic symptoms.
The symptoms have been present continuously for 2 months.
Duration is the primary differentiating factor among brief psychotic disorder (<1 month), schizophreniform disorder (1-6 months), and schizophrenia (>6 months).
4
Evaluate for the presence of concurrent mood episodes.
The patient has no significant depressive or manic symptoms.
The absence of mood episodes rules out schizoaffective disorder and bipolar/depressive disorders with psychotic features.

Key Concept

Differentiation of psychotic disorders based on symptom duration and the relationship to substance use cessation.
Question 805Question →

A 26-year-old woman, G2P1, at 14 weeks gestation, comes to the clinic for an initial prenatal visit. She reports daily intravenous heroin use and states, "I want to stop using to protect my baby." Her last heroin use was 16 hours ago, and she currently exhibits yawning, rhinorrhea, and piloerection. Her medical history includes bipolar I disorder, but she stopped her mood stabilizer prior to conception. Over the past three weeks, she has experienced a pervasive low mood, anhedonia, and fatigue. She is adamant about not being admitted to the hospital, fearing she will be fired from her job if she misses work. Vital signs are within normal limits. Arterial blood gas analysis on room air shows:

- pH: 7.447.44
- PaCO 2_2: 30 mm Hg30\text{ mm Hg}
- PaO 2_2: 102 mm Hg102\text{ mm Hg}
- HCO 3−_3^-: 20 mEq/L20\text{ mEq/L}

Which of the following is the most appropriate next step in the management of this patient?

Show answer & explanation

Answer: Initiate outpatient buprenorphine therapy

Answer

The correct action is to initiate outpatient buprenorphine therapy.
The correct answer addresses the immediate need to stabilize the patient's opioid use disorder safely during pregnancy. The standard of care for pregnant patients with opioid use disorder is opioid agonist therapy (OAT) using either buprenorphine or methadone. Medically supervised withdrawal (detoxification) is generally contraindicated because it carries a high risk of relapse and can cause significant fetal distress or demise during periods of acute withdrawal. Since the patient has decision-making capacity and refuses inpatient admission, starting buprenorphine in the outpatient setting respects her autonomy while providing the safest evidence-based treatment for both her and the fetus.

Step-by-Step Solution

1
Identify the primary clinical problem and patient's pregnancy status
The patient has active Opioid Use Disorder (OUD), is experiencing mild withdrawal, and is in the first trimester of pregnancy.
Pregnancy alters the standard management options for OUD due to severe fetal risks associated with acute opioid withdrawal.
2
Determine the standard of care for OUD during pregnancy
Opioid agonist therapy (OAT) with buprenorphine or methadone is indicated, while medically supervised withdrawal (detoxification) is avoided.
OAT prevents maternal withdrawal, reduces the risk of relapse to illicit opioids, and prevents withdrawal-induced fetal distress or demise.
3
Evaluate the ethical constraints and patient preferences regarding the setting of care
The patient refuses inpatient admission but retains decision-making capacity.
Competent pregnant patients cannot be forced into involuntary treatment solely for fetal benefit, making outpatient initiation of buprenorphine the safest, most ethical, and most appropriate next step.

Key Concept

The standard of care for opioid use disorder in pregnancy is opioid agonist therapy (buprenorphine or methadone). Medically supervised withdrawal is avoided due to the high risk of relapse and fetal distress. Furthermore, competent pregnant patients cannot be ethically forced into involuntary treatment against their will.
Question 806Question →

Match each clinical presentation of a severe adverse drug reaction to the psychotropic medication most likely responsible.

Click a left item, then click its matching right item

Items

A 28-year-old woman with bipolar disorder presents with a rapidly spreading, blistering rash and mucosal ulcerations. Vitals: T 38.2°C (100.8°F), HR 105/min. Mental status: anxious but oriented. Symptoms began shortly after her medication dose was aggressively increased.
A 34-year-old man with treatment-resistant schizophrenia develops a severe sore throat and chills. Vitals: T 39.4°C (102.9°F), HR 112/min. Mental status: baseline restricted affect. Laboratory testing reveals an absolute neutrophil count of 300/mm³.
A 42-year-old man on maintenance therapy for bipolar disorder complains of urinating up to 7 liters of dilute urine daily. Vitals: BP 110/70 mm Hg, HR 88/min. Mental status: cooperative, euthymic mood. Serum sodium is 146 mEq/L.
A 22-year-old woman with bipolar disorder presents with severe epigastric pain radiating to the back and intractable nausea. Vitals: T 37.8°C (100.0°F), HR 115/min. Mental status: distressed and tearful. Serum lipase is markedly elevated.
A 45-year-old man with major depressive disorder presents with palpitations, neck stiffness, and profuse sweating shortly after eating aged meats and cheeses. Vitals: BP 215/125 mm Hg, HR 122/min. Mental status: highly anxious.

Matches

Show answer & explanation

Answer

The blistering mucosal rash matches with Lamotrigine; the fever and severe neutropenia match with Clozapine; the massive output of dilute urine matches with Lithium; the epigastric pain with elevated lipase matches with Valproate; and the hypertensive crisis matches with Phenelzine.
Each clinical vignette describes a classic, severe adverse effect uniquely associated with a specific psychotropic medication. Recognizing these distinct toxicities is crucial because they require immediate discontinuation of the offending agent and specialized supportive care.

Step-by-Step Solution

1
Evaluate the first vignette (blistering rash, mucosal ulcerations, fever after rapid medication increase).
Diagnose Stevens-Johnson syndrome, which is strongly associated with rapid titration of Lamotrigine.
Lamotrigine requires a strict, slow titration schedule to mitigate the high risk of severe dermatologic reactions.
2
Evaluate the second vignette (fever, sore throat, and dangerously low absolute neutrophil count).
Diagnose agranulocytosis, an idiosyncratic reaction strongly associated with Clozapine.
Clozapine carries a black box warning for severe neutropenia and agranulocytosis, necessitating mandatory registry and regular hematologic monitoring.
3
Evaluate the third vignette (excessive thirst, polyuria of dilute urine, mild hypernatremia).
Diagnose nephrogenic diabetes insipidus, a very common complication of Lithium.
Lithium antagonizes antidiuretic hormone (ADH) in the renal collecting tubules, impairing the kidney's ability to concentrate urine.
4
Evaluate the fourth vignette (epigastric pain radiating to the back, nausea, elevated lipase).
Diagnose acute pancreatitis, a known, potentially fatal adverse effect of Valproate.
Valproic acid has a distinct black box warning for acute pancreatitis, which can occur at any point during treatment.
5
Evaluate the fifth vignette (severe hypertension, palpitations, and diaphoresis after consuming aged foods).
Diagnose tyramine-induced hypertensive crisis.
MAOIs such as phenelzine prevent the breakdown of dietary tyramine, leading to massive catecholamine release and severe hypertension.

Key Concept

Identifying severe, life-threatening adverse effects of psychotropic medications
Question 807Question →

A 34-year-old man comes to the outpatient clinic requesting assistance with substance use cessation. He has been crushing and snorting prescription oxycodone daily for the past two years and recently transitioned to intravenous heroin use. He states, 'I want to get clean, but the withdrawals are unbearable.' His last opioid use was approximately 16 hours ago. His medical history is significant for a major depressive episode at age 25, for which he was prescribed fluoxetine 20 mg daily, which he continues to take. Upon further psychiatric history, he recalls a distinct three-week period during college when he slept only two hours a night, aggressively day-traded stocks leading to bankruptcy, and felt 'invincible.' He also notes occasional paranoia that undercover police are tracking his phone, but this only occurs when he is actively attempting to purchase illicit drugs. He is employed as a financial analyst and mentions, 'My manager is getting suspicious of my erratic hours, but I haven't told anyone at work about my problem.' Vital signs are temperature 37.1°C (98.8°F), blood pressure 142/88 mmHg, pulse 110/min, and respirations 18/min. Physical examination reveals mydriasis, frequent yawning, rhinorrhea, and prominent piloerection. Which of the following is the most appropriate next step in the management of this patient?

Show answer & explanation

Answer: Administer sublingual buprenorphine-naloxone

Answer

Administer sublingual buprenorphine-naloxone
The correct next step is to administer sublingual buprenorphine-naloxone. This patient has Opioid Use Disorder and is presenting in active, mild-to-moderate opioid withdrawal (evidenced by mydriasis, yawning, rhinorrhea, piloerection, and tachycardia 16 hours after his last heroin use). Buprenorphine is a partial mu-opioid receptor agonist with a high receptor affinity. It is a first-line medication for the treatment of Opioid Use Disorder. Because of its high affinity, it can displace full agonists (like heroin or oxycodone) from the receptor. Therefore, it must be initiated only after a patient is exhibiting objective signs of withdrawal; otherwise, it can precipitate acute withdrawal. Since this patient is already in withdrawal, buprenorphine induction is appropriate and will safely relieve his symptoms while providing maintenance therapy. Naloxone is included in the formulation to deter intravenous misuse, as it is poorly absorbed sublingually but active if injected.

Step-by-Step Solution

1
Identify the primary clinical syndrome.
The patient is presenting with Opioid Use Disorder and is currently experiencing acute opioid withdrawal.
Vital signs show tachycardia and mild hypertension, alongside physical findings of mydriasis, yawning, rhinorrhea, and piloerection, which are classic for opioid withdrawal following cessation 16 hours ago.
2
Determine the most appropriate pharmacotherapy for the current state.
Sublingual buprenorphine-naloxone is the best choice.
Buprenorphine, a partial opioid agonist, is indicated for maintenance therapy in Opioid Use Disorder. It must be initiated when the patient is in active mild-to-moderate withdrawal (as seen here) to avoid precipitating withdrawal.
3
Rule out alternative interventions.
Naltrexone is contraindicated currently, SSRIs are risky given the bipolar history, antipsychotics are not indicated for situational paranoia, and breaching confidentiality is unethical.
Each alternative violates a pharmacological principle, psychiatric diagnostic timeline, or ethical guideline.

Key Concept

Buprenorphine is a partial opioid agonist used for medication-assisted treatment of Opioid Use Disorder and should be initiated when a patient exhibits objective signs of active opioid withdrawal.
Question 808Question →

A 28-year-old man is brought to the emergency department with acute-onset confusion, severe diaphoresis, and shivering. He recently started taking tramadol for a back injury while on a maintenance dose of citalopram. Vital signs include temperature 39.2°C (102.6°F), blood pressure 168/98 mmHg, and heart rate 124/min. Physical examination reveals generalized hyperreflexia and inducible ankle clonus. Arrange the following steps in the correct sequential order for the evidence-based management of this patient's condition.

Drag items to arrange them in the correct order

Show answer & explanation

Answer

The correct sequence for managing serotonin syndrome is to first discontinue the offending serotonergic agents, followed by initiating supportive care, then administering intravenous benzodiazepines for initial symptom control, and finally administering cyproheptadine if symptoms remain refractory.
The algorithm for serotonin syndrome progresses logically from the least invasive and most critical causative step (stopping the offending agent) to fundamental supportive measures, followed by first-line pharmacological symptom control with benzodiazepines. Targeted antidotes like cyproheptadine are strictly reserved for moderate-to-severe cases that are refractory to standard supportive care and sedation.

Step-by-Step Solution

1
Diagnose the patient's acute toxidrome based on the clinical presentation.
The combination of an SSRI (citalopram) and an analgesic with serotonergic properties (tramadol), along with altered mental status, autonomic hyperactivity, and neuromuscular irritability (hyperreflexia and clonus), confirms the diagnosis of serotonin syndrome.
An accurate diagnosis dictates the specific toxidrome management algorithm.
2
Determine the immediate first priority in management.
Discontinuation of all serotonergic agents.
Removing the precipitating pharmacological cause is essential to halt the progression of the toxicity.
3
Determine the sequence of subsequent supportive and pharmacological interventions.
Supportive care must be established first, followed by benzodiazepines, and then cyproheptadine.
Supportive care stabilizes vital signs; benzodiazepines directly treat the agitation and hyperreflexia safely; cyproheptadine is a specific antidote utilized only when these initial measures fail to control symptoms.

Key Concept

Algorithm for the acute management of Serotonin Syndrome
Question 809Question →

A 26-year-old woman is evaluated in the emergency department for a painful rash, fever, and generalized malaise that began two days ago. She has a history of bipolar I disorder that has been stable for two years on a maintenance regimen of divalproex sodium. Six weeks ago, she experienced a major depressive episode, and her psychiatrist initiated an additional mood-stabilizing medication. The new medication was started at a standard dose of 25 mg daily for two weeks, followed by an increase to 50 mg daily. On physical examination, her temperature is 38.6°C (101.5°F). There is a widespread, erythematous, maculopapular eruption on her face, trunk, and extremities, with scattered areas of epidermal sloughing. Painful erosions are present on her buccal mucosa. Which of the following pharmacokinetic effects of the patient's maintenance medication on the newly added drug most likely precipitated this patient's current condition?

Show answer & explanation

Answer: Inhibition of hepatic glucuronidation

Answer

Inhibition of hepatic glucuronidation
The patient's presentation of fever, widespread epidermal sloughing, and mucosal erosions is highly characteristic of Stevens-Johnson syndrome (SJS). In psychiatric practice, lamotrigine is notorious for causing SJS, particularly if titrated too rapidly. This patient was on maintenance divalproex sodium (valproate) and was started on a standard lamotrigine titration schedule. Valproate is a potent inhibitor of UDP-glucuronosyltransferase (UGT), the hepatic enzyme responsible for metabolizing lamotrigine. By inhibiting glucuronidation, valproate roughly doubles the half-life and serum concentration of lamotrigine. To prevent SJS, patients taking valproate must be started on a modified, slower lamotrigine titration schedule (typically 25 mg every other day for the first two weeks). The failure to account for this pharmacokinetic inhibition resulted in rapid lamotrigine accumulation and subsequent SJS.

Step-by-Step Solution

1
Identify the patient's clinical presentation.
The patient has fever, malaise, a widespread maculopapular rash with epidermal sloughing, and mucosal erosions.
These findings are the classic presentation of Stevens-Johnson syndrome (SJS), a life-threatening mucocutaneous reaction.
2
Determine the most likely offending agent based on the psychiatric history.
The patient was recently started on a new mood stabilizer for bipolar depression. Given the risk of SJS, the new medication is almost certainly lamotrigine.
Lamotrigine is a first-line agent for bipolar depression and carries a black box warning for serious skin rashes, including SJS.
3
Analyze the drug-drug interaction occurring with the patient's maintenance medication.
The patient is on maintenance divalproex sodium (valproate). Valproate inhibits UDP-glucuronosyltransferase (UGT).
UGT is the primary enzyme responsible for the hepatic metabolism of lamotrigine.
4
Connect the pharmacokinetic interaction to the clinical outcome.
Because valproate inhibits UGT, lamotrigine clearance is reduced and its half-life is doubled. The psychiatrist used a standard titration schedule instead of the required slower schedule (e.g., 25 mg every other day), leading to toxic lamotrigine levels and precipitating SJS.
Rapid dose escalation of lamotrigine, especially in the presence of a UGT inhibitor like valproate, drastically increases the risk of SJS.

Key Concept

Valproate inhibits hepatic glucuronidation (via UGT enzymes), which doubles the half-life of lamotrigine. When co-administering these medications, the lamotrigine titration schedule must be slowed by 50% to mitigate the risk of Stevens-Johnson syndrome.
Estimated Time:1m 30s
Question 810Question →

A psychiatric hospital is updating its standardized clinical pathways for medication safety. Match each psychotropic medication with the most appropriate baseline or ongoing screening modality required to monitor its specific adverse effect profile.

Click a left item, then click its matching right item

Items

Clozapine
Lithium
Valproate
Ziprasidone

Matches

Show answer & explanation

Answer

Clozapine pairs with absolute neutrophil count; Lithium pairs with thyroid-stimulating hormone; Valproate pairs with serum transaminases; and Ziprasidone pairs with electrocardiogram.
Each psychotropic medication listed requires a distinct monitoring parameter based on its unique side effect profile: clozapine requires absolute neutrophil count for agranulocytosis, lithium requires thyroid-stimulating hormone for hypothyroidism, valproate requires serum transaminases for hepatotoxicity, and ziprasidone requires an electrocardiogram for QTc prolongation.

Step-by-Step Solution

1
Identify the primary dose-limiting or life-threatening adverse effect associated with each psychotropic medication.
Clozapine can cause agranulocytosis, lithium causes hypothyroidism, valproate causes hepatotoxicity, and ziprasidone causes QTc prolongation.
Understanding the distinct toxicity profile is necessary to select the correct screening test.
2
Correlate the identified adverse effect with the corresponding laboratory test or diagnostic study.
Agranulocytosis requires absolute neutrophil count, hypothyroidism requires thyroid-stimulating hormone, hepatotoxicity requires transaminases, and QTc prolongation requires an electrocardiogram.
Clinical guidelines mandate specific surveillance testing to prevent severe morbidity from these agents.

Key Concept

Routine safety monitoring for psychotropic medications is dictated by their distinct adverse effect profiles.
Question 811Question →

A 4444-year-old man is evaluated in the hospital for progressive agitation and confusion. He was admitted two days ago for a severe right lower extremity cellulitis caused by methicillin-resistant Staphylococcus aureus (MRSA) and was started on intravenous linezolid. He has a history of major depressive disorder and generalized anxiety disorder, for which he takes multiple stable home medications. His temperature is 39.1∘C39.1^\circ\text{C} (102.4∘F102.4^\circ\text{F}), blood pressure is 168/102168/102 mmHg, pulse is 124124/min, and respirations are 2222/min. Physical examination reveals profuse diaphoresis, bilateral mydriasis, and a resting tremor. Neurological examination is notable for pronounced hyperreflexia in the lower extremities and sustained ankle clonus. A dangerous interaction with which of the following of the patient's home medications is the most likely cause of this presentation?

Show answer & explanation

Answer: Fluoxetine

Answer

Fluoxetine
This patient's presentation of altered mental status, autonomic instability (hyperthermia, tachycardia, hypertension, diaphoresis), and prominent neuromuscular hyperactivity (hyperreflexia and clonus) is classic for serotonin syndrome. The syndrome was precipitated by the administration of linezolid. Linezolid is an antibiotic used to treat resistant Gram-positive infections (like MRSA) that also acts as a reversible, non-selective monoamine oxidase inhibitor (MAOI). When combined with a serotonergic agent like an SSRI (e.g., fluoxetine), it blocks the breakdown of serotonin, leading to massive synaptic accumulation and toxicity. Clinicians must carefully review psychiatric medication lists before initiating linezolid therapy.

Step-by-Step Solution

1
Evaluate the clinical presentation.
The patient has altered mental status, autonomic instability (fever, tachycardia, hypertension, diaphoresis), and neuromuscular hyperactivity (hyperreflexia, sustained clonus).
Identifying the clinical triad points directly to a diagnosis of serotonin syndrome.
2
Analyze the patient's recent medication changes.
The patient was recently started on intravenous linezolid for an MRSA infection.
Linezolid is an oxazolidinone antibiotic that also possesses reversible, non-selective monoamine oxidase inhibitor (MAOI) properties.
3
Identify the contraindicated home medication.
Combining an MAOI (linezolid) with a selective serotonin reuptake inhibitor (SSRI) like fluoxetine creates a dangerous drug-drug interaction.
The concurrent use of these medications leads to impaired serotonin degradation and increased serotonin release, resulting in synaptic serotonin toxicity (serotonin syndrome).

Key Concept

Serotonin syndrome can be precipitated by combining a selective serotonin reuptake inhibitor (SSRI) with linezolid, an antibiotic that possesses monoamine oxidase inhibitor (MAOI) activity.
Question 812Question →

A consultation-liaison psychiatry team is reviewing common adverse effects of various psychotropic medications to update hospital safety protocols. Match each clinical presentation of an adverse drug reaction with the medication most likely responsible.

Click a left item, then click its matching right item

Items

Polyuria, polydipsia, new-onset fine tremor, and elevated thyroid-stimulating hormone (TSH).
Excessive sialorrhea, generalized tonic-clonic seizures, and severe neutropenia.
Rapidly spreading maculopapular exanthem with oral mucosal blistering and epidermal detachment.
Acute altered mental status, asterixis, and hyperammonemia in the setting of elevated transaminases.

Matches

Show answer & explanation

Answer

The presentations match as follows: polyuria/tremor/hypothyroidism with Lithium; sialorrhea/seizures/neutropenia with Clozapine; mucosal blistering rash with Lamotrigine; and hyperammonemic encephalopathy with Valproate.
Each psychotropic medication has a distinct adverse effect profile that is critical for clinical monitoring. Lithium causes nephrogenic diabetes insipidus and hypothyroidism. Clozapine causes agranulocytosis and lowers the seizure threshold. Lamotrigine can cause Stevens-Johnson syndrome. Valproate can cause hyperammonemic encephalopathy and hepatotoxicity.

Step-by-Step Solution

1
Analyze the first clinical presentation (polyuria, tremor, elevated TSH).
Identified as lithium-induced adverse effects.
Lithium affects renal concentrating ability (nephrogenic DI) and thyroid gland function, and commonly causes a fine tremor.
2
Analyze the second presentation (sialorrhea, seizures, neutropenia).
Identified as clozapine toxicity.
Clozapine is unique among antipsychotics for causing agranulocytosis, hypersalivation, and a significantly increased risk of seizures.
3
Analyze the third presentation (mucosal blistering, epidermal detachment).
Identified as Stevens-Johnson syndrome/Toxic epidermal necrolysis caused by lamotrigine.
Lamotrigine is strongly associated with life-threatening rashes, particularly if titrated too rapidly.
4
Analyze the fourth presentation (hyperammonemia, hepatotoxicity, asterixis).
Identified as valproate-induced hyperammonemic encephalopathy.
Valproate interferes with the urea cycle, leading to hyperammonemia and subsequent encephalopathy presenting with asterixis.

Key Concept

Adverse effect profiles of psychotropic medications
Question 813Question →

A 2121-year-old woman is evaluated in the primary care clinic for a three-month history of persistent sadness, hypersomnolence, and low energy. She also mentions a strong desire to quit smoking cigarettes but has been unsuccessful with nicotine replacement therapy. Her temperature is 37.0∘C37.0^\circ\text{C} (98.6∘F98.6^\circ\text{F}), blood pressure is 105/70 mmHg105/70\text{ mmHg}, and pulse is 84/min84/\text{min}. Her body mass index is 18.4 kg/m218.4\text{ kg/m}^2. Physical examination is notable for bilateral parotid gland hypertrophy, enamel erosion on her lingual tooth surfaces, and hyperkeratotic calluses on the dorsum of her right hand. Laboratory results show a serum potassium of 3.2 mEq/L3.2\text{ mEq/L}. The physician is considering a pharmacologic intervention that can address both her mood disorder and tobacco dependence. Which of the following medications is most strongly contraindicated in this patient?

Show answer & explanation

Answer: Bupropion

Answer

Bupropion
Bupropion is a norepinephrine-dopamine reuptake inhibitor (NDRI) frequently utilized for treating major depressive disorder and for smoking cessation. However, a major adverse effect of bupropion is that it lowers the seizure threshold in a dose-dependent manner. Because of this risk, bupropion is absolutely contraindicated in patients with seizure disorders and those with a history of anorexia nervosa or bulimia nervosa. This patient's presentation features hypokalemia, parotid gland hypertrophy, dental enamel erosion, and calluses on the dorsum of the hand (Russell sign), which are all classic signs of bulimia nervosa with self-induced vomiting. The electrolyte abnormalities (e.g., hypokalemia, hyponatremia) inherent to purging behaviors structurally increase the risk of seizures, making the administration of bupropion exceptionally dangerous.

Step-by-Step Solution

1
Analyze the patient's physical examination and laboratory findings to identify any underlying, undiagnosed conditions.
The patient has parotid gland hypertrophy, dental enamel erosion, calluses on the dorsum of the right hand (Russell sign), and hypokalemia. These findings are classic for bulimia nervosa with recurrent self-induced vomiting.
Identifying the comorbid condition is crucial because eating disorders strongly dictate which psychopharmacologic agents are safe to use.
2
Determine the clinical indications for the medications being considered.
The physician is seeking a medication that treats both depression and tobacco dependence, which strongly suggests bupropion as the intended agent.
Understanding the primary indication helps evaluate the appropriateness of the chosen therapy.
3
Evaluate the safety and contraindications of bupropion in the context of the patient's bulimia nervosa.
Bupropion is an absolute contraindication in patients with eating disorders due to an unacceptably high risk of triggering seizures, especially in the presence of electrolyte derangements like hypokalemia.
Medication safety must be prioritized over dual-indication benefits when absolute contraindications exist.

Key Concept

Bupropion is absolutely contraindicated in patients with eating disorders (such as anorexia nervosa or bulimia nervosa) because it lowers the seizure threshold, and these patients are already at increased risk for seizures due to electrolyte imbalances.
Estimated Time:1m 15s
Question 814Question →

A 28-year-old woman comes to the psychiatry clinic complaining of a 4-week history of severely depressed mood, hypersomnolence, hyperphagia, and feeling that her "limbs are weighed down by lead." She has been unable to attend her job as an accountant for the past two weeks. Her medical history is notable for a psychiatric hospitalization three years ago when she was brought to the emergency department by police after staying awake for six consecutive days, spending her entire life savings on lottery tickets, and telling bystanders she was a "prophet of wealth." She was stabilized on a medication at that time but discontinued it one year ago because she disliked the required routine blood tests. She currently takes no medications and uses no illicit substances. Which of the following is the most appropriate next step in pharmacotherapy for this patient?

Show answer & explanation

Answer: Initiate quetiapine

Answer

Initiate quetiapine
This patient has a history of a manic episode characterized by grandiosity, decreased need for sleep, and impulsivity requiring hospitalization, which definitively establishes a diagnosis of bipolar I disorder. She was likely previously treated with lithium, given her aversion to routine blood tests. She is currently presenting with a major depressive episode. The treatment of bipolar depression differs significantly from unipolar major depressive disorder. First-line monotherapy options for bipolar depression include quetiapine, lurasidone, cariprazine, and lamotrigine (though lamotrigine requires slow titration and is not ideal for acute, severe symptoms). The correct answer recommends initiating quetiapine, which is an atypical antipsychotic with robust evidence for efficacy in acute bipolar depression.

Step-by-Step Solution

1
Analyze the patient's psychiatric history to establish a correct diagnosis.
The patient has a history of a severe manic episode (decreased need for sleep, grandiosity, impulsive spending requiring hospitalization) three years ago.
A single manic episode confirms the diagnosis of bipolar I disorder, regardless of current symptoms.
2
Evaluate the patient's current clinical presentation.
The patient is currently experiencing a major depressive episode with atypical features (hypersomnolence, hyperphagia, leaden paralysis).
Identifying the current phase of bipolar disorder dictates the appropriate pharmacological intervention.
3
Select the appropriate evidence-based pharmacotherapy for the current phase.
Quetiapine is selected as the optimal treatment.
First-line monotherapy options for bipolar depression include quetiapine, lurasidone, cariprazine, or the olanzapine-fluoxetine combination. Antidepressant monotherapy must be avoided.

Key Concept

Patients with bipolar I disorder presenting with a major depressive episode should be treated with mood stabilizers or atypical antipsychotics approved for bipolar depression (e.g., quetiapine, lurasidone) rather than antidepressant monotherapy to avoid precipitating a manic switch.
PreviousPage 41 / 41
Psychiatry Practice Questions — USMLE Step 2 CK — Page 41 | Examkin